CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025
Portfolio Pulse from Benzinga Newsdesk
CMS has granted a Transitional Pass-Through Payment for Medtronic's Symplicity Spyral Renal Denervation Catheter, effective for up to three years starting January 1, 2025. This aims to enhance patient access to innovative technology.
November 01, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's Symplicity Spyral Renal Denervation Catheter has received a Transitional Pass-Through Payment from CMS, effective for up to three years starting January 1, 2025. This regulatory approval supports patient access to this innovative technology.
The CMS approval for Transitional Pass-Through Payment is a significant regulatory milestone for Medtronic, as it facilitates patient access to their innovative Symplicity Spyral RDN Catheter. This is likely to positively impact Medtronic's stock price in the short term due to the enhanced market potential and recognition of the product's innovation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100